Budesonide MMX: Completed Phase III enrollment

Santarus completed enrollment of 510 patients in a double-blind, U.S. Phase III trial comparing 6 and 9 mg of oral budesonide MMX daily vs. placebo. The study also includes an arm receiving 2.4 g/day ...